May 8th 2024
SMART uses an ICS and a long-acting beta-2 agonist (LABA) product, giving patients 4 years and older with moderate to severe uncontrolled persistent asthma 1 inhaler for dual symptom relief.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More